Metabolic Dysfunction-Associated Steatotic Liver Disease

From a shift in nomenclature for steatotic liver disease to how a boom in live biotherapeutics will revamp treatment for Clostridioides difficile infection, Healio was at the forefront of gastroenterology and hepatology coverage in 2023.

The renaming of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease to metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease is a long time coming.

In June 2023, 74% of respondents from a multinational, multisociety Delphi process agreed that the term nonalcoholic fatty liver disease was “sufficiently flawed” and 89% preferred nomenclature that described the underlying cause of disease.

BOSTON — Although primary care physicians play a vital role in managing metabolic dysfunction-associated steatotic liver disease, many are not following guidance on screening, risk stratification or referrals, according to research.

BOSTON — Patients with metabolic dysfunction-associated steatotic liver disease who underwent bariatric surgery lost less weight over 5 years than those without MASLD, according to research presented at The Liver Meeting.

BOSTON — Treatment with aldafermin 3 mg appeared to be well-tolerated and significantly reduced Enhance Liver Fibrosis score after 48 weeks among patients with metabolic dysfunction-associated steatohepatitis, according to a presenter.

BOSTON — Treatment with efruxifermin resulted in “clinically meaningful” but not yet statistically significant benefit at 36 weeks in cirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to late-breaking data.

BOSTON — Treatment with retatrutide at 8 mg and 12 mg resulted in substantial reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease, according to a presenter at The Liver Meeting.

Increased consumption of ultra-processed foods was associated with higher odds of developing metabolic dysfunction-associated steatotic liver disease in both adolescents and adults, according to research presented at The Liver Meeting.

BOSTON — Low-dose aspirin significantly reduced steatosis in patients with metabolic dysfunction-associated steatotic liver disease and improved markers of liver inflammation and fibrosis, according to data presented at The Liver Meeting.